This Stock Can Double; Top Experts Said Buy Or Do SIP On Every 10% To 12% Correction
Mankind Pharma Ltd (NSE: MANKIND) Wealth Creation Pick: Stock markets had a weak start on Friday (22 March). Sensex slipped more than 200 points in early trade. Nifty also fell below the important level of 22000.
The pressure on the stock market is due to the IT sector. There is a good opportunity for wealth creation in the long term amidst the slowdown in the market.
An expert has made pharma sector company Mankind Pharma his Wealth Creation Pick.
A stock with solid fundamentals could give strong returns in the long term. This stock’s return was 25 percent over the past six months.
Mankind Pharma: What Does The Expert Think?
Expert says, that today Mankind Pharma is from the pharma space in wealth creation. This is a pharma cum FMCG company. This company has strong promoters. Ahuja Family is very old and has a strong hold over the business.
The company is among the biggest pharma companies on the domestic market. Sun Pharma is the company’s largest domestic pharma business.
The best thing about this is that about 97 percent of its business is from India. It is therefore not concerned with the concerns of USFDA.
As a domestic company, they don’t have any legal expenses on an international level.
In general, R&D costs and litigation expenses (legal) account for the majority of pharma company expenditures.
He claims that Mankind Pharma is a leader in the pharmaceutical market. Around 40 brands are available.
Many of the brands they have are market leaders. The dealer network of the company is strong.
According to the data from September 2023 and the December 2023 period, both DII’s and FII’s share has increased.
This is a positive sign. This company’s financial history is strong. In the last five years, the revenue has grown at a rate of 16 percent per year, and the profit at a rate of 12 percent per year.
The growth is steady and positive. The company’s growth forecast is strong. An outlook of double-digit growth has been kept for the financial year 2025-26.
In this way, there can be good growth in the next two years. The balance seat is strong. The company has cash of around Rs 2750 crore.
Net cash flow is around Rs 650 crore. The company needs only Rs 500 crore capex. That means the company does not need to take a loan.
Mankind Pharma: Anil Singhvi’s Targets
Expert says, due to good valuations, there will be more upside in the stock from here.
The company will make EBITDA of Rs 2500 crore in this financial year. Can make a profit of around Rs 1800 crore. This stock is trading at 25/26 time on FY 2025 valuation.
It is not very expensive. In this way, the stock has to be bought with a perspective of 1 to 3 years.
The stock is expected to double in three or four years, with a 20-25 percent growth. Mankind Pharma’s short-term target is Rs 2700.
The medium target is Rs 3300 and long term target is Rs 4000. SIP has to be done in this share for every 10 percent fall.
Buy this stock comfortably when the market mood is bad. Top Experts Said Buy Or Do SIP On Every 10% To 12% Correction.
Mankind Pharma: Share Performance
The stock of Mankind Pharma has seen a rise over the past six years. The stock returned 25 percent in the last six-month period.
The stock has increased by 12 percent over the past three months. Stocks have increased by approximately 10% in the first half of this year.
Mankind Pharma’s 52-week high is 2,297 and the low is 1,240. The BSE capitalization of this company is over Rs. 87,364 crore.
About Mankind Pharma Ltd Company
Mankind Pharma Limited is a pharmaceutical company based in India.
The Company manufactures and markets a wide range of pharmaceutical formulations for acute and chronic therapies, & consumer healthcare products.
It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, anti-diabetic, vitamins/minerals/nutrients, gastrointestinal, respiratory, dermatology, gynecology, and pain/analgesics.
Its other therapeutic areas include urology, ophthalmology, stomatological, antiparasitic, antineoplastic, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, anti-tuberculosis, parenteral, and vaccines.
The company’s portfolio includes brands such as Telmikind (Rx), Nurokind (Rx), G Amlokind (Rx), Glimestar, Asthakind, Gudcef (Moxikind), Candiforce, Codistar, Mahacef, Dydroboon, Cefakind, Monticope, Zenflox, Dynaglipt, and many others.
Fundamental Analysis of Mankind Pharma Ltd
| Market Cap | ₹ 88,620 Cr. |
| Current Price | ₹ 2,214 |
| 52-wk High | ₹ 2,297 |
| 52-wk Low | ₹1,241 |
| Stock P/E | 53.7 |
| Book Value | ₹ 216 |
| Dividend | 0.00 % |
| ROCE | 20.7 % |
| ROE | 17.0 % |
| Face Value | ₹ 1.00 |
| P/B Value | 10.2 |
| OPM | 24.0 % |
| EPS | ₹ 41.2 |
| Debt | ₹ 9.74 Cr. |
| Debt to Equity | 0.00 |
Mankind Pharma Ltd Share Price Target 2024 To 2030
| Year | 1st Target | 2nd Target |
| 2024 | ₹2200 | ₹2514 |
| 2025 | ₹2615 | ₹2748 |
| 2026 | ₹2899 | ₹3000 |
| 2027 | ₹3215 | ₹3425 |
| 2028 | ₹3648 | ₹3855 |
| 2029 | ₹3944 | ₹4000 |
| 2030 | ₹4215 | ₹4487 |
Mankind Pharma Ltd Shareholding Pattern
| Promoters Holding | |
| June 2023 | 76.50% |
| Sept 2023 | 76.50% |
| Dec 2023 | 76.50% |
| FII Holding | |
| June 2023 | 4.18% |
| Sept 2023 | 4.18% |
| Dec 2023 | 6.74% |
| DII Holding | |
| June 2023 | 4.65% |
| Sept 2023 | 4.56% |
| Dec 2023 | 9.78% |
| Public Holding | |
| June 2023 | 14.67% |
| Sept 2023 | 14.76% |
| Dec 2023 | 6.97% |
Mankind Pharma Ltd Share: Last 5 Years’ Financial Condition
To gain a better understanding of how the market is performing, let’s look at the outlook of this share in the previous years.
However, investors should be aware of the risks and the market conditions before making any investment decision.
Last 5 Years’ Sales:
| 2019 | ₹3,829 Cr |
| 2020 | ₹4,794 Cr |
| 2021 | ₹5,523 Cr |
| 2022 | ₹7,486 Cr |
| 2023 | ₹8,984 Cr |
Last 5 Years’ Net Profit:
| 2019 | ₹514 Cr |
| 2020 | ₹958 Cr |
| 2021 | ₹1,084 Cr |
| 2022 | ₹1,389 Cr |
| 2023 | ₹1,650 Cr |
Last 5 Years’ Debt-To-Equity Ratio:
| 2019 | 0.06 |
| 2020 | 0 |
| 2021 | 0.02 |
| 2022 | 0.11 |
| 2023 | 0 |
Last 10 Years’ Profit Growth:
| 10 Years: | – |
| 5 Years: | 12% |
| 3 Years: | 9% |
| Current Year: | 39% |
Last 10 years’ Return on Equity (ROE):
| 10 Years: | – |
| 5 Years: | 22% |
| 3 Years: | 21% |
| Last Year: | 17% |
Sales Growth Over 10 Years:
| 10 Years: | – |
| 5 Years: | 16% |
| 3 Years: | 19% |
| Current Year: | 14% |
Conclusion
This article is a complete guide about Mankind Pharma Ltd Share.
These information and forecasts are based on our analysis, research, company fundamentals and history, experiences, and various technical analyses.
Also, We have talked in detail about the share’s future prospects and growth potential.
Hopefully, these informations will help you in your further investment.
If you are new to our website and want to get all the latest updates related to the stock market, join us on Telegram Group.
If you have any further queries, please comment below. We will be happy to answer all your questions.
If you like this information, share the article with as many people as possible.
Disclaimer: Dear readers, we’d like to inform you that we are not authorized by SEBI (Securities and Exchange Board of India). The information on this site is only for informational and educational purposes and shouldn’t be considered financial advice or stock recommendations. Also, the share price predictions are completely for reference purposes. The price predictions will only be valid when there are positive signs on the market. Any uncertainty about the company’s future or the current state of the market will not be considered in this study. We are not responsible for any financial loss you might incur through the information on this site. We are here to provide timely updates about the stock market and financial products to help you make better investment choices. Do your own research before any investment.
